In epilepsy, higher risk of early death varies based on severity, other factors

A new study has found that people with epilepsy have an increased risk of early death and the increased risk varies depending on where they live, the number of medications they take, and what other diseases they may have. The study is published in the March 22, 2023, online issue of Neurology^®, the medical journal of the American Academy of Neurology.

“Our research found an increased risk even among those who do not have other health problems and are taking only one medication to control their seizures,” said study author Seo-Young Lee MD PhD, of Kangwon National University in Chuncheon, Republic of Korea.

For the study, researchers used a national health database to identify 138,998 people who were newly treated for epilepsy. Then they examined the national death register and found of all study participants, 20,095 died during the 10-year study period. Participants had an average age of 49 at the start of the study.

Researchers documented causes of death for participants. They also documented factors such as age, sex, where a person lived, and the number of medications they had been prescribed. They then calculated the overall mortality rates for study participants. Mortality rate is a measure of the number of deaths in a specific population. Mortality rates for study participants were compared to the mortality rates for the general population.

Among study participants, there were nearly 660,000 person-years, which represents both the number of people in the study and the amount of time each person spends in the study. For that number of person-years, there were 20,095 deaths in study participants compared to an expected 8,929 deaths among the general population.

Using person-years to calculate risk, researchers found that people with epilepsy had more than twice the risk of death compared to the overall population. The increased risk was even higher in younger people in the study.

In addition, people with epilepsy living in rural areas had a 247% increased risk of death compared to the general population while those living in urban areas had a 203% increased risk.

Study participants taking just one antiseizure medication had a 156% increased risk of death compared to the general population while people taking four or more antiseizure medications had a nearly five times greater risk.

People with epilepsy who had no other diseases or health concerns had a 161% increased risk of death compared to the general population. However, people with epilepsy who had been hospitalized never or only once had no increased risk of premature death.

Among study participants who died, 19% died of cerebrovascular disease, which was a 4.5 times greater risk of death than the general population, 16% died of cancers outside of the central nervous system, a 137% greater risk and 7% died of cancers of the central nervous system, a 46 times greater risk. Lee notes that such cancers and cerebrovascular disease are mostly presumed to be underlying causes of epilepsy. In addition, 6% died of pneumonia, 7% died of external causes such as falls, accidents, and drowning and 2% died of suicide, all of which were a two times greater risk. Epilepsy and status epilepticus accounted for 2% of overall deaths.

“Our study demonstrated a wide range of mortality risks in people with epilepsy, depending on age, disease duration, disease severity, and other health conditions,” said Lee. “We also identified disparities for people living in rural areas and urge public health efforts to improve accessibility to care. Active control of seizures, education about injury prevention, monitoring for suicidal thoughts, and efforts to improve accessibility to epilepsy care all contribute to reducing mortality.”

A limitation of the study was that participants were residents of Korea, so the results may not be generalizable to people living in other countries. Also, researchers only included participants who were treated with antiseizure medications for six months or more, so they could not assess deaths that occurred in the first six months of treatment.

The study was funded by the Soonchunhyang University Research Fund and the and the Korean Ministry of Health & Welfare.

Source: News Release
American Academy of Neurology
March 22, 2023